Moleculin Biotech, Inc. MBRX

MBRX Company Overview

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of oncology therapeutics and antiviral technologies. The company operates primarily in the biotechnology and drug development industries, with an emphasis on hard-to-treat cancers and infectious diseases. Its core strategy centers on advancing proprietary drug candidates through clinical development while targeting areas with significant unmet medical need. Revenue generation has historically been limited because the company remains in the development stage and has not reported sustained commercial product sales in public filings.

The company’s primary development programs include Annamycin, a next-generation anthracycline designed to avoid multidrug resistance mechanisms and reduce cardiotoxicity associated with traditional anthracyclines, and WP1066, an immune/transcription modulator investigated for brain tumors and other cancers. Moleculin has also explored antiviral applications through compounds such as WP1122. The company was founded in 2015 and is headquartered in Houston, Texas. Since inception, it has evolved from an early-stage oncology platform into a clinical-stage biotechnology company focused on advancing multiple therapeutic candidates through U.S. and international clinical trials.